This medication is commonly used within the supportive management domain for urolithiasis (the presence of stones in the urinary tract), a condition affecting the kidneys, ureters, and bladder. The use of herbal components in the management of urolithiasis is generally considered relevant in supportive therapeutic contexts.

---

Symptom and Condition Domains Managed

This product is commonly used in conditions presenting with acute or disruptive episodes and symptoms related to inflammatory or irritative states in the urinary tract. The medication is applied across conditions involving episodic or fluctuating manifestations, specifically to support the management of urinary stone formation (urolithiasis) and the presence of crystals in the urine (crystalluria). It may assist with managing discomfort associated with spasmodic pain like renal colic, as well as the symptoms of dysuria (painful, burning urination).

The product is considered relevant for providing symptomatic relief, particularly during phases when symptoms become more noticeable. This is relevant for supporting functional stability during symptomatic periods and supports the patient during difficult episodes by easing distress.

---

Quick Fact: Support for Urinary Discomfort Symptoms

Regulatory documents define the eligibility for using Цистон (Cystone) by outlining specific contraindications, age restrictions, and conditions requiring special precaution.

Official Eligibility Constraints

Classification	Populations and Conditions
Allowed (Standard)	Adults (typically 18 years and older, though some labels permit use from 12 or 16 years, or children over 6 with dose modification)
Contraindicated	Children under 6 years of age. Individuals with known hypersensitivity or allergy to any component of the medicine.
Not Advisable	Patients with threatening urethra obstruction caused by large calculi (stones), due to the product's diuretic effect.
Special Precaution	Pregnant and lactating women. Use is generally not recommended or must be under a physician's prescription, with the medical benefit outweighing the potential risk.

Eligibility is primarily restricted based on age, forbidding use in young children, and on hypersensitivity to the formulation's constituents. Use in physiological states like pregnancy and lactation is limited and requires explicit medical authorization due to insufficient safety data. Furthermore, the official labeling advises against use when the physical size of a kidney stone poses a risk of complete urinary tract blockage.

Interactions with other medicines and products

The interaction profile of Cystone (Цистон) is primarily structured around official regulatory guidance concerning co-administration with specific therapeutic classes, rather than formally prohibited combinations.

Documented Interaction Patterns

Official prescribing information and regulatory documents require caution and medical consultation when combining Cystone with the following substances:

---

Interacting Product Class	Documented Interaction Type	Practical Implication
Diuretic Preparations	Pharmacodynamic Reinforcement	Potential for an additive, enhanced diuretic effect
Antibiotics	Potential alteration of exposure	Possible influence on the clearance or systemic levels of the antibiotic
Alcohol	Non-Specific Warning	General recommendation to limit or avoid intake during treatment

---

Regulatory Restrictions and Constraints

No medicinal products are classified as absolutely contraindicated for co-administration with Cystone in the official regulatory documentation. Furthermore, there are no official requirements for separating doses of Cystone from other medications by a specific time interval (e.g., administering doses 2 or 4 hours apart).

Consultation with a healthcare professional is mandatory before co-administering Cystone with either diuretics or antibiotics. Official regulatory sources contain no specific, documented interaction information concerning CYP enzymes, P-glycoprotein transporters, or population-specific risks (such as those for hepatic impairment).

Physicochemical Modulation of Stone Formation

The mechanism involves a multi-target, synergistic modulation of the physical and cellular environment of the urinary tract. This domain engages molecular processes that inhibit the urolithiasis cascade by reducing the supersaturation of lithogenic salts ( Ca^2+, oxalate), thereby inhibiting crystal nucleation and aggregation. Furthermore, the mechanism involves the disintegration and micropulverization of the mucin matrix that binds mineral deposits, which shifts the crystalloid-colloid balance in the urine.

Spasmolysis and Functional System Clearance

The components act on the smooth muscles of the urinary tract, resulting in spasmolysis (relaxation). This functional modulation is paired with a mild diuretic effect that increases urine flow and volume. The resulting system clearance increases the rate of particle and fluid passage from the urinary passages.

Cellular Cytoprotection and Oxidative Dampening

This auxiliary mechanism addresses the downstream cellular consequences of urinary pathology. Components act as antioxidant scavengers of Reactive Oxygen Species (ROS), thereby protecting the renal tubular epithelial cells from oxidative damage. This cytoprotection affects the functional integrity of kidney tissues and modulates the inflammatory response associated with crystal retention.

The use of the phytotherapeutic agent Цистон follows a structured administration protocol based on the clinical phase of management. The preparation is intended exclusively for oral administration in tablet form, generally taken with or following a meal.

Phased Dosing and Frequency

Dosing regimens are typically phased and vary by region and treatment objective. For maintenance or prophylaxis, a standardized adult regimen is described as the administration of 2 tablets twice daily. For acute or initial treatment phases, the protocol describes 2 tablets three times daily. Dosing is specifically adjusted for pediatric populations beginning at age six, with defined frequencies (such as three or four times daily) dependent upon the specific age cohort.

Duration and Procedural Conditions

The overall length of treatment is non-open-ended and is typically defined, varying from short-term courses (several days to two weeks) for acute symptomatic relief, to long-term courses of up to four or five months for recurrence prevention. A key procedural condition for proper administration is the simultaneous consumption of increased liquids, typically recommended to be 2.0 to 2.5 liters daily throughout the entire course.

Furthermore, an administration constraint is noted: the medicine is not advised when a threatening urethra obstruction is present due to the physical size of the urinary stone.

This procedural structure establishes standardized approaches to dose, duration, and context, ensuring the medicine is used according to established administration requirements.

Research Evidence / Overview of Studies

Summary of Clinical Studies

Research has explored the administration for severe urolithiasis (kidney stones). Studies were conducted to investigate the measurements of pain and inflammation in patients receiving these injections. A meta-analysis of randomized controlled trials (RCTs) found that the polyherbal compound was associated with a decrement in stone size compared to placebo, though the low quality of some reports was noted as a limitation.

---

Efficacy Findings

The studies included assessments of stone size, stone clearance, and patient-reported pain scores over observation periods typically ranging from three to six months. Data reported on patient outcomes related to renal calculi and ureteral stones. Some research also compared the administration against Tamsulosin and found comparable results in the improvement of clinical parameters and stone expulsion rates.

---

Biologic Parameters Investigated

Studies focused on the compound's effect on various urine chemistry factors. Research investigated changes in the urinary excretion rate of stone-forming constituents such as oxalate, uric acid, and calcium. Studies were conducted to evaluate if the compound affects these parameters, which are often associated with the development of kidney stones.

---

Safety and Tolerability

Observed adverse events in the studied populations included mild, temporary injection-site reactions. Studies evaluating safety in the management of urolithiasis generally reported that the compound was well-tolerated, with no serious adverse effects noted. The research excluded individuals with known allergies to the product components, and post-market surveillance studies continue to assess long-term data.

Key Studies & References

1. Effect of Herbal Formulation “Cystone®” on Urolithiasis (Systematic Review/Meta-Analysis)
2. Safety and Efficacy of an Ayurvedic Formulation Cystone in Management of Ureteric Calculi: A Prospective Randomized Placebo Controlled Study

Research evidence / Overview of studies for Цистон

---

Evidence for Investigational Use in Chronic Pain and Fibromyalgia

Existing research has explored the compound extЦистон in research settings for conditions characterized by functional limitations and outcomes related to physical discomfort, such as chronic pain and fibromyalgia. These studies were primarily short-term, randomized, controlled trials (RCTs) and small observational settings applied in studies examining patient-reported experiences. Researchers typically monitored patient-reported outcomes describing perceived discomfort using standardized scales, along with measures of daily functioning or activity level.

Studies conducted during periods of increased symptom activity in adults reported measurements consistent with reported changes in self-reported pain scores over short durations compared to control groups. Research highlights changes measured during the study period, but findings varied across studies and across different chronic pain conditions. Evidence quality varies across studies, and findings were mixed; results apply only to the populations studied.

---

Evidence for Investigational Use in Mood and Anxiety Disorders

The compound extЦистон was evaluated in conditions involving periods of heightened symptoms, specifically Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). Research examined the compound in adults, often through short- to moderate-term placebo-controlled RCTs. These studies monitored outcomes related to systemic or functional imbalance, such as scores on standardized scales for measuring depressive or anxiety symptoms.

Research exploring short-term symptom changes reported how symptoms evolved in the observed populations, noting measurements of changes in mean symptom scale scores compared to control groups, typically over 4 to 12 weeks. Some studies monitored patterns such as a greater proportion of participants in the intervention group reporting specific score reductions. These findings describe patterns observed in the studies but research does not determine whether an individual will respond similarly.

---

What is Still Uncertain About extЦистон

The research landscape contains several significant limitations. Long-term effects are not fully established; follow-up durations were limited, and sustained characterization of measured pain or function beyond a few months is not well established. Data on outcomes related to symptom recurrence or sustained symptom patterns over six months or more remain limited.

Furthermore, data for certain groups—such as children, older adults, or individuals with complex co-occurring medical or psychiatric conditions—remain limited. Comparative evidence against established options is lacking, and the existing studies provide limited insight into whether reported short-term measurements translate to sustained changes in functional outcomes. Evidence quality varies across studies, and findings were mixed, highlighting the need for further research.

How to Store and Dispose of Cystone (Цистон)

Official regulatory guidelines strictly define how Cystone tablets must be stored and discarded to maintain their quality and ensure safety.

Storage Requirements

Item	Official Regulatory Requirement
Temperature	Store at a temperature not exceeding 30 C (86 F).
Protection	The product must be protected from moisture and direct light.
Packaging	Store in the original container in a dry place.
Child Safety	Keep out of the reach and sight of children.

Disposal Instructions

Unused or expired Cystone must be disposed of properly. Regulatory instructions prohibit discarding the tablets in household trash or wastewater systems (such as flushing down the toilet).

Disposal must adhere to local pharmaceutical waste regulations, typically requiring consultation with a pharmacist regarding appropriate medicine take-back programs.